Un­pack­ing the Aduhelm de­ci­sion, Ver­tex's half full glass, a $525M J&J breakup, and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

By now you have sure­ly read about the FDA’s con­tro­ver­sial ap­proval of Bio­gen’s Alzheimer’s drug and all its re­ver­ber­a­tions. But I’d still rec­om­mend check­ing out the meaty re­cap be­low to make sure you didn’t miss all the an­gles that the End­points team has cov­ered. If you’d rather look ahead, look no fur­ther than our three-day vir­tu­al pan­els next week at BIO, where we will dis­cuss what the new nor­mal means for every part of the in­dus­try.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.